Skip to main content
Erschienen in: Annals of Surgical Oncology 4/2008

01.04.2008 | Breast Oncology

Frequent Deletion and Methylation in SH3GL2 and CDKN2A Loci are Associated with Early- and Late-onset Breast Carcinoma

verfasst von: Satyabrata Sinha, MSc, Neelanjana Chunder, PhD, Nupur Mukherjee, MSc, Neyaz Alam, MS, Anup Roy, MD, Susanta Roychoudhury, PhD, Chinmay Kumar Panda, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

This study attempts to understand the association of candidate tumour suppressor genes SH3GL2, CDKN2A (p16–p14) and CDKN2B (p15) in development of early-onset (group A) and late-onset (group B) breast carcinoma (BC).

Methods

Deletion, methylation, and mutation of the candidate tumour suppressor genes (TSGs) were analysed in 47 group A and 59 group B samples. Immunohistochemical analysis was used to identify the expression status of SH3GL2 and p16. Clinicopathological correlation of the alterations was analysed by the chi-square and log-rank tests.

Results

Higher frequency of overall alterations (46–62%) in SH3GL2 and p16-p14 than p15 (22–26%) indicated their importance in BC. Deletion frequencies were in the following order: group A: p14 (43%) > p16 (42%) > SH3GL2 (38%) > p15 (33%) and group B: p14 (36%) > p16 (33%) > SH3GL2 (31%) > p15 (14%) while, methylation frequencies were: group A: SH3GL2 (34%) > p16 (28%) > p14 (26%) > p15 (15%) and group B: SH3GL2 (36%) > p16 (31%) > p14 (29%) > p15 (15%). Infrequent mutation was observed only in CDKN2A common exon-2. Immunohistochemical analysis showed significant association between expression of SH3GL2 and p16 with their deletion (P = 0.01 and 0.02, respectively) and methylation status (P = 0.007 and 0.01, respectively). In group A, overall alterations of SH3GL2 showed significant association with CDKN2A locus with significant prognostic implications, whereas CDKN2A and CDKN2B loci were associated in both groups.

Conclusions

The molecular mechanisms involving CDKN2A inactivation seem to follow similar pathway in the pathogenesis of both age groups of BC while significant association of SH3GL2 with CDKN2A might play a synergistic role in the development of group A.
Literatur
1.
Zurück zum Zitat Sen U, Sankaranarayanan R, Mandal S, et al. Cancer patterns in eastern India: The first report of the Kolkata Cancer Registry. Int J Cancer. 2002;100:86–91.PubMedCrossRef Sen U, Sankaranarayanan R, Mandal S, et al. Cancer patterns in eastern India: The first report of the Kolkata Cancer Registry. Int J Cancer. 2002;100:86–91.PubMedCrossRef
2.
Zurück zum Zitat Chunder N, Mandal S, Basu D, et al. Deletion mapping of chromosome 1 in early onset and late onset breast tumors–a comparative study in eastern India. Pathol Res Pract. 2003;199:313–21.PubMedCrossRef Chunder N, Mandal S, Basu D, et al. Deletion mapping of chromosome 1 in early onset and late onset breast tumors–a comparative study in eastern India. Pathol Res Pract. 2003;199:313–21.PubMedCrossRef
3.
Zurück zum Zitat Chunder N, Mandal S, Roy A, et al. Analysis of different deleted regions in chromosome 11 and their interrelations in early- and late-onset breast tumors: association with cyclin D1 amplification and survival. Diagn Mol Pathol. 2004;13:172–82.PubMedCrossRef Chunder N, Mandal S, Roy A, et al. Analysis of different deleted regions in chromosome 11 and their interrelations in early- and late-onset breast tumors: association with cyclin D1 amplification and survival. Diagn Mol Pathol. 2004;13:172–82.PubMedCrossRef
4.
Zurück zum Zitat Foo CS, Su D, Chong CK, et al. Breast cancer in young Asian women: study on survival. ANZ J Surg. 2005;75:566–72.PubMedCrossRef Foo CS, Su D, Chong CK, et al. Breast cancer in young Asian women: study on survival. ANZ J Surg. 2005;75:566–72.PubMedCrossRef
5.
Zurück zum Zitat Nessling M, Richter K, Schwaenen C, et al. Candidate genes in breast cancer revealed by microarray based comparative genomic hybridization of archived tissue. Cancer Res. 2005;65:439–47.PubMed Nessling M, Richter K, Schwaenen C, et al. Candidate genes in breast cancer revealed by microarray based comparative genomic hybridization of archived tissue. Cancer Res. 2005;65:439–47.PubMed
6.
Zurück zum Zitat Marsk KL, Varley JM. Loss of heterozygosity at chromosome 9p in ductal carcinoma in situ and invasive carcinoma of the breast. Br J Cancer. 1998;77:1439–47. Marsk KL, Varley JM. Loss of heterozygosity at chromosome 9p in ductal carcinoma in situ and invasive carcinoma of the breast. Br J Cancer. 1998;77:1439–47.
7.
Zurück zum Zitat Eiriksdottir G, Sigurdsson A, Jonasson JG, et al. Loss of heterozygosity on chromosome 9 in human breast cancer: association with clinical variables and genetic changes at other chromosome regions. Int J Cancer. 1995;64:378–82.PubMedCrossRef Eiriksdottir G, Sigurdsson A, Jonasson JG, et al. Loss of heterozygosity on chromosome 9 in human breast cancer: association with clinical variables and genetic changes at other chromosome regions. Int J Cancer. 1995;64:378–82.PubMedCrossRef
8.
Zurück zum Zitat An HX, Claas A, Savelyeva L, et al. Two regions of deletion in 9p23–24 in sporadic breast cancer. Cancer Res. 1999;59:3941–3.PubMed An HX, Claas A, Savelyeva L, et al. Two regions of deletion in 9p23–24 in sporadic breast cancer. Cancer Res. 1999;59:3941–3.PubMed
9.
Zurück zum Zitat Sharpless NE, DePinho RA. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev. 1999;9:22–30.PubMedCrossRef Sharpless NE, DePinho RA. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev. 1999;9:22–30.PubMedCrossRef
10.
Zurück zum Zitat Dikic I. Mechanisms controlling EGF receptor endocytosis and degradation. Biochem Soc Trans. 2003;31:1178–81.PubMedCrossRef Dikic I. Mechanisms controlling EGF receptor endocytosis and degradation. Biochem Soc Trans. 2003;31:1178–81.PubMedCrossRef
11.
Zurück zum Zitat Xu L, Sgroi D, Sterner CJ, et al. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. Cancer Res. 1994;54:5262–4.PubMed Xu L, Sgroi D, Sterner CJ, et al. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. Cancer Res. 1994;54:5262–4.PubMed
12.
Zurück zum Zitat Brenner AJ, Aldaz CM. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res. 1995;55:2892–5.PubMed Brenner AJ, Aldaz CM. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res. 1995;55:2892–5.PubMed
13.
Zurück zum Zitat An HX, Niederacher D, Picard F, et al. Frequent allele loss on 9p21–22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer. Gene Chromosomes Can. 1996;17:14–20.CrossRef An HX, Niederacher D, Picard F, et al. Frequent allele loss on 9p21–22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer. Gene Chromosomes Can. 1996;17:14–20.CrossRef
14.
Zurück zum Zitat Quesnel B, Fenaux P, Philippe N, et al. Analysis of p16 gene deletion and point mutation in breast carcinoma. Br J Cancer. 1995;72:351–3.PubMed Quesnel B, Fenaux P, Philippe N, et al. Analysis of p16 gene deletion and point mutation in breast carcinoma. Br J Cancer. 1995;72:351–3.PubMed
15.
Zurück zum Zitat Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/ MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995;55:4525–30.PubMed Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/ MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995;55:4525–30.PubMed
16.
Zurück zum Zitat Roa JC, Anabalon L, Tapia O, et al. Promoter methylation profile in breast cancer. Rev Med Chil. 2004;132:1069–77.PubMed Roa JC, Anabalon L, Tapia O, et al. Promoter methylation profile in breast cancer. Rev Med Chil. 2004;132:1069–77.PubMed
17.
Zurück zum Zitat Silva J, Silva JM, Dominguez G, et al. Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J Pathol. 2003;199:289–97.PubMedCrossRef Silva J, Silva JM, Dominguez G, et al. Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J Pathol. 2003;199:289–97.PubMedCrossRef
18.
Zurück zum Zitat Brenner AJ, Paladugu A, Wang H, et al. Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer. Clin Cancer Res. 1996;2:1993–8.PubMed Brenner AJ, Paladugu A, Wang H, et al. Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer. Clin Cancer Res. 1996;2:1993–8.PubMed
19.
Zurück zum Zitat Herman JG, Jen J, Merlo A, et al. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 1996;56:722–7.PubMed Herman JG, Jen J, Merlo A, et al. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 1996;56:722–7.PubMed
20.
Zurück zum Zitat Pollock PM, Welch J, Hayward NK. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Res. 2001;61:1154–61.PubMed Pollock PM, Welch J, Hayward NK. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Res. 2001;61:1154–61.PubMed
21.
Zurück zum Zitat Giordani L, Iolascon A, Servedio V, et al. Two regions of deletion in 9p22–p24 in neuroblastoma are frequently observed in favorable tumors. Cancer Genet Cytogenet. 2002;135:42–7.PubMedCrossRef Giordani L, Iolascon A, Servedio V, et al. Two regions of deletion in 9p22–p24 in neuroblastoma are frequently observed in favorable tumors. Cancer Genet Cytogenet. 2002;135:42–7.PubMedCrossRef
22.
Zurück zum Zitat Sobin LH, Wittekind C. (eds) TNM Classification of Malignant Tumors, 6th ed. New York: Wiley; 2002 Sobin LH, Wittekind C. (eds) TNM Classification of Malignant Tumors, 6th ed. New York: Wiley; 2002
23.
Zurück zum Zitat Pandey M, Singh SP, Behere PB, et al. Quality of life in patients with early and advanced carcinoma of the breast. Eur J Surg Oncol. 2000;26:20–4.PubMedCrossRef Pandey M, Singh SP, Behere PB, et al. Quality of life in patients with early and advanced carcinoma of the breast. Eur J Surg Oncol. 2000;26:20–4.PubMedCrossRef
24.
Zurück zum Zitat Dasgupta S, Mukherjee N, Roy S, et al. Mapping of candidate tumor suppressor genes’ loci on human chromosome 3 in head and neck squamous cell carcinoma of Indian patient population. Oral Oncol. 2002;38:6–15.PubMedCrossRef Dasgupta S, Mukherjee N, Roy S, et al. Mapping of candidate tumor suppressor genes’ loci on human chromosome 3 in head and neck squamous cell carcinoma of Indian patient population. Oral Oncol. 2002;38:6–15.PubMedCrossRef
25.
Zurück zum Zitat Tripathi Bhar A, Banerjee S, Chunder N, et al. Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients. J Can Res Clin Oncol. 2003;129:642–50.CrossRef Tripathi Bhar A, Banerjee S, Chunder N, et al. Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients. J Can Res Clin Oncol. 2003;129:642–50.CrossRef
26.
Zurück zum Zitat Ichimura K, Bolin MB, Goike HM, et al. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res. 2000;60:417–24.PubMed Ichimura K, Bolin MB, Goike HM, et al. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res. 2000;60:417–24.PubMed
27.
Zurück zum Zitat Singh RK, Indra D, Mitra S, et al. Deletions in chromosome 4 differentially associated with the development of cervical cancer: evidence of slit2 as a candidate tumor suppressor gene. Hum Genet. 2007;122:71–81.PubMedCrossRef Singh RK, Indra D, Mitra S, et al. Deletions in chromosome 4 differentially associated with the development of cervical cancer: evidence of slit2 as a candidate tumor suppressor gene. Hum Genet. 2007;122:71–81.PubMedCrossRef
28.
Zurück zum Zitat Boynton RF, Blount PL, Yin J, et al. Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci USA. 1992;89:3385–8.PubMedCrossRef Boynton RF, Blount PL, Yin J, et al. Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci USA. 1992;89:3385–8.PubMedCrossRef
29.
Zurück zum Zitat Ivanova T, Petrenko A, Gritsko T, et al. Methylation and silencing of the retinoic acid receptor-β2 gene in cervical cancer. BMC Cancer. 2002;2:4.PubMedCrossRef Ivanova T, Petrenko A, Gritsko T, et al. Methylation and silencing of the retinoic acid receptor-β2 gene in cervical cancer. BMC Cancer. 2002;2:4.PubMedCrossRef
30.
Zurück zum Zitat Heyman M, Rasool O, Brandter LB, et al. Prognostic importance of p15INK4B and p16INK4 gene inactivation in childhood acute lymphocytic leukemia. J Clin Oncol. 1996;14:1512–20.PubMed Heyman M, Rasool O, Brandter LB, et al. Prognostic importance of p15INK4B and p16INK4 gene inactivation in childhood acute lymphocytic leukemia. J Clin Oncol. 1996;14:1512–20.PubMed
31.
Zurück zum Zitat Tannapfel A, Sommerer F, Benicke M, et al. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. J Pathol. 2002;197:624–31.PubMedCrossRef Tannapfel A, Sommerer F, Benicke M, et al. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. J Pathol. 2002;197:624–31.PubMedCrossRef
32.
Zurück zum Zitat Milde-Langosch K, Bamberger AM, Rieck G, et al. Overexpression of the p16 cell cycle inhibitor in breast cancer associated with a more malignant phenotype. Breast Cancer Res Treat. 2001;67:61–70.PubMedCrossRef Milde-Langosch K, Bamberger AM, Rieck G, et al. Overexpression of the p16 cell cycle inhibitor in breast cancer associated with a more malignant phenotype. Breast Cancer Res Treat. 2001;67:61–70.PubMedCrossRef
33.
Zurück zum Zitat Berggren de Verdier PJ, Kumar R, Adolfsson J, et al. Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer. Scand J Urol Nephrol. 2006;40:363–9.CrossRef Berggren de Verdier PJ, Kumar R, Adolfsson J, et al. Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer. Scand J Urol Nephrol. 2006;40:363–9.CrossRef
34.
Zurück zum Zitat Geisler SA, Olshan AF, Weissler MC, et al. p16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res. 2002;8:3445–53.PubMed Geisler SA, Olshan AF, Weissler MC, et al. p16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res. 2002;8:3445–53.PubMed
35.
Zurück zum Zitat Shang C, Fu WN, Guo Y, et al. Study of the SH3-domain GRB2-like 2 gene expression in laryngeal carcinoma. Chin Med. J 2007;120:385–8.PubMed Shang C, Fu WN, Guo Y, et al. Study of the SH3-domain GRB2-like 2 gene expression in laryngeal carcinoma. Chin Med. J 2007;120:385–8.PubMed
36.
Zurück zum Zitat Silva J, Dominguez G, Silva JM, et al. Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. Oncogene. 2001;20:4586–90.PubMedCrossRef Silva J, Dominguez G, Silva JM, et al. Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. Oncogene. 2001;20:4586–90.PubMedCrossRef
37.
Zurück zum Zitat Bisogna M, Calvano JE, Ho GH, et al. Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas. Cancer Genet Cytogenet. 2001;125:131–8.PubMedCrossRef Bisogna M, Calvano JE, Ho GH, et al. Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas. Cancer Genet Cytogenet. 2001;125:131–8.PubMedCrossRef
38.
Zurück zum Zitat Hewitt C, Lee Wu C, Evans G, et al. Germline mutation of ARF in a melanoma kindred. Hum Mol Genet. 2002;11:1273–9.PubMedCrossRef Hewitt C, Lee Wu C, Evans G, et al. Germline mutation of ARF in a melanoma kindred. Hum Mol Genet. 2002;11:1273–9.PubMedCrossRef
Metadaten
Titel
Frequent Deletion and Methylation in SH3GL2 and CDKN2A Loci are Associated with Early- and Late-onset Breast Carcinoma
verfasst von
Satyabrata Sinha, MSc
Neelanjana Chunder, PhD
Nupur Mukherjee, MSc
Neyaz Alam, MS
Anup Roy, MD
Susanta Roychoudhury, PhD
Chinmay Kumar Panda, PhD
Publikationsdatum
01.04.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 4/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9790-0

Weitere Artikel der Ausgabe 4/2008

Annals of Surgical Oncology 4/2008 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.